How to Read This Page
"Best peptides" lists online usually rank by popularity or by what a seller stocks. This one ranks by human evidence and regulatory status, and it links to our deeper guide on each compound. It does not name vendors and it does not give doses.
Evidence levels used below
| Level | Meaning |
|---|---|
| Strong | Large randomized controlled trials and an FDA label for the use in question |
| Approved, narrow | FDA-approved, but for a specific condition that isn't the goal people search for |
| Phase 3 | Late-stage trials reported; not yet approved |
| Early human | Small pilot studies, case series or single-center trials |
| Preclinical | Cells and animals only |
Regulatory status
- Approved: an FDA-approved drug exists (prescription required).
- Investigational: in clinical trials; no legal supply.
- PCAC-recommended: in July 2026, FDA's Pharmacy Compounding Advisory Committee recommended the substance for the 503A compounding list. This is not approval and FDA has not finished rulemaking. See after the PCAC votes.
- Not approved: no approved product; sold only as "research use only," which is not legal for human use.
The first rule for reading any row: if the evidence column says "preclinical," the claims you've seen online come from rats or cells, not people. If you're new to the category, start with what are peptides.
Weight Loss and Metabolic Health
| Peptide | Human evidence | Status | Guide |
|---|---|---|---|
| Semaglutide (Wegovy) | Strong: 14.9% mean weight loss at 68 weeks in STEP 1 | Approved (2021; oral 2025) | Semaglutide guide |
| Tirzepatide (Zepbound) | Strong: up to 20.9% at 72 weeks in SURMOUNT-1 | Approved (2023) | What is tirzepatide |
| Orforglipron (Foundayo) | Strong: Phase 3 ATTAIN program (small molecule, not a peptide) | Approved (April 2026) | Foundayo guide |
| Retatrutide | Phase 3: 24.2% at 48 weeks in Phase 2; TRIUMPH Phase 3 reported 2026 | Investigational; Lilly filing planned Q1 2027 | Retatrutide guide |
| MOTS-c | Preclinical / early human: rodent exercise and metabolism data | PCAC-recommended; not approved | MOTS-c guide |
| AOD-9604 | Early human: small trials, no convincing weight-loss effect | Not approved | AOD-9604 guide |
Bottom line: this is the one goal where peptides have real proof, and the proven ones are prescription drugs. Full hub: peptides for weight loss.
Injury Recovery, Tendons and Joints
| Peptide | Human evidence | Status | Guide |
|---|---|---|---|
| BPC-157 | Early human: three small pilot studies; a 16-patient knee chart review | PCAC-recommended; on FDA's compounding safety-risk list | BPC-157 knee pain study |
| TB-500 (thymosin β4 fragment) | Preclinical: most data is on full-length Tβ4, not the fragment | PCAC-recommended; on FDA's safety-risk list | TB-500 after PCAC |
| Wolverine blend (BPC-157 + TB-500) | None for the blend | Not approved | Wolverine stack explained |
| KLOW / GLOW blends | None for the blends | Not approved | KLOW guide, GLOW guide |
Bottom line: the most-searched recovery peptides have the thinnest human data. A 2026 scoping review by orthopaedic surgeons found two-thirds of the literature was animal work and human results were modest at best.
Muscle, Growth Hormone and Body Composition
| Peptide | Human evidence | Status | Guide |
|---|---|---|---|
| Tesamorelin (Egrifta) | Approved, narrow: reduces visceral fat in HIV-associated lipodystrophy | Approved (2010) for that use only | What tesamorelin does |
| Sermorelin | Approved, then discontinued: Geref was approved in the 1990s and is listed by FDA as discontinued | Not currently marketed as an approved drug | Sermorelin guide |
| CJC-1295 / ipamorelin | Early human / preclinical: GH-release pharmacology studies, no body-composition outcome trials | Not approved | CJC-1295 + ipamorelin stack |
| IGF-1 LR3 | Preclinical: lab-modified IGF-1, no human trials | Not approved | IGF-1 LR3 guide |
Bottom line: no peptide is approved for building muscle in healthy adults. Growth-hormone secretagogues raise GH in short studies; whether that changes body composition safely over time hasn't been shown. Note also that GLP-1 drugs cause lean-mass loss alongside fat loss; see the lean mass meta-analysis.
Skin, Hair and Cosmetic
| Peptide | Human evidence | Status | Guide |
|---|---|---|---|
| GHK-Cu (topical) | Early human: small skin studies with creams and serums | Cosmetic ingredient; injectable form on FDA's safety-risk list | GHK-Cu and healing |
| GHK-Cu (injectable) | Preclinical for systemic use | Not approved | GHK-Cu guide |
Bottom line: the copper peptide evidence is topical. Injectable GHK-Cu borrows that reputation without the data.
Cognition and Mood
| Peptide | Human evidence | Status | Guide |
|---|---|---|---|
| Semax | Early human: mostly Russian studies, never reviewed by FDA | PCAC-recommended; not approved in the U.S. | Semax after PCAC |
| Selank | Early human: Russian anxiety studies | Not approved in the U.S. | Selank guide |
| Adamax | Preclinical | Not approved | Adamax vs Semax |
Bottom line: the nootropic peptides have trials, but small ones from a single country, rarely replicated. FDA has not evaluated any of them.
Sleep and Longevity
| Peptide | Human evidence | Status | Guide |
|---|---|---|---|
| DSIP (emideltide) | Early human, decades old, inconsistent | PCAC did not recommend it (July 2026) | DSIP rejection explained |
| Epitalon | Early human: mostly from one research group | PCAC-recommended; not approved | Epitalon after PCAC |
| SS-31 (elamipretide) | Approved, narrow: Barth syndrome (Forzinity, Sept 2025) | Approved for that use only | What is SS-31 |
| MOTS-c | Preclinical / early human | PCAC-recommended; not approved | Mitochondrial peptide primer |
Bottom line: "longevity peptide" claims rest on cell and animal data. Elamipretide is the exception, and its approval is for a rare mitochondrial disease, not aging.
Sexual Health
| Peptide | Human evidence | Status | Guide |
|---|---|---|---|
| Bremelanotide / PT-141 (Vyleesi) | Strong for its indication: two Phase 3 trials in premenopausal women with HSDD | Approved (2019); not approved for men | PT-141 guide |
Bottom line: PT-141 is approved, but only for one condition in one population, with cardiovascular contraindications a prescriber must screen for.
